Clinical trials: Healthy Subjects;Overweight or Obesity
Diabetes Mellitus, Type 2, Obesity
Investigation Of Weight Loss And Body Composition Changes After Dosing With Either Placebo Or One Of Two Active Drugs
The drugs GSK189075 and GW869682 result in increased caloric losses. This study is investigating how if taken over 8 weeks that affects weight loss, food intake and the composition of the body.
- Trial name
- NCT00494767
- Testing
- GW869682, GSK189075
- Where
- United Kingdom
- Volunteers
- 27 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Obesity
Effect of VI-0521 (Qsymia®) on Glomerular Filtration Rate (GFR) in Overweight or Obese Healthy Subjects
The main purpose of this study is measure the effect of VI-0521 on kidney function. Specifically, glomerular filtration rate (GFR) will be measured at baseline, after 4 weeks of study treatment, and after an additional 4 weeks of…
- Trial name
- NCT02229214
- Testing
- Qsymia
- Where
- United States
- Volunteers
- 51 people, healthy volunteers welcome
- Sponsor
- VIVUS LLC
Obese or Overweight Healthy Volunteers
Clinical Study to Assess the Safety and Efficacy of ACV Moringa Effervescent Tablet Intake on Weight Management in Overweight and Class I Obese Study Participants
A Randomized, Double-Blind, Placebo-Controlled, Two-Arm, Single-Centre, Clinical Study to Evaluate the Safety and Efficacy of Intake of ACV Moringa on the Degree of Weight Change in Overweight and Class I Obese Study Participants
- Trial name
- NCT07098624
- Testing
- ACV Moringa Effervescent Tablets 4.3 g
- Volunteers
- 66 people
- Sponsor
- NovoBliss Research Pvt Ltd
Healthy Participants, Obesity
A Study to Investigate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AZD1043 in Healthy Adult Participants Living With Overweight and/or Obesity.
The purpose of the study is to assess the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of AZD1043 following single and multiple ascending doses in healthy adult participants living with overweight and/or…
- Trial name
- NCT07511205
- Testing
- AZD1043
- Where
- 3 sites in United States, United Kingdom
- Volunteers
- 104 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Overweight or Obese
A Study to Evaluate MWN109 Injection in Healthy Subjects
This study is a Phase1, randomized, double-blinded, and placebo-controlled study. In each cohort, enrolled participants will be randomized to receive either placebo or MWN109.
- Trial name
- NCT06859853
- Testing
- Subcutaneous single and mutiple dose
- Where
- Australia
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- Shanghai Minwei Biotechnology Co., Ltd
Obesity and Overweight
A First-in-human Study of HCR-188 in Overweight or Obese Otherwise Healthy Volunteers Without Type 2 Diabetes
This is a first-in-human study evaluating the safety, tolerability, pharmacokinetics, immunogenicity and pharmacodynamics of single and multiple doses of HCR-188 administered as subcutaneous injection(s).
- Trial name
- NCT06845943
- Testing
- HCR-188
- Where
- Australia
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Helicore Biopharma, Inc.
Healthy Participants, Normal Weight Adults
Blood Glucose Levels After Bread Consumption Between Participants With Normal Weight and Overweight/Obesity
Obesity and increased blood glucose peaks are risk factors for type 2 diabetes mellitus (T2DM). Few studies have explored whether increased body fat contributes to higher blood glucose peaks after food consumption.
- Conditions
- Healthy Participants, Normal Weight Adults, Overweight or Obese Adults
- Trial name
- PPGRB (NCT07158762)
- Testing
- White bread, Wholemeal bread
- Where
- United Kingdom
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- City, University of London
Healthy
A Study Of PF-04620110 As A Modified-Release Formulation In Healthy Overweight Or Obese Subjects
The primary purpose of this trial is to evaluate the safety and tolerability, pharmacokinetics and pharmacodynamics, of multiple oral doses of PF-04620110 as a modified-release formulation.
- Trial name
- NCT01474941
- Where
- Belgium
- Volunteers
- 27 people, healthy volunteers welcome
- Sponsor
- Pfizer
Overweight and Obesity
Safety, Tolerability, and Pharmacokinetics of a Single or Multiple Ascending Doses of CPX101
This randomized, double-blind, placebo-controlled Phase I clinical study was designed to evaluate the tolerability and safety, PK profile, immunogenicity of CPX101 in a single dose in healthy participants and multiple doses in…
- Trial name
- NCT06545162
- Where
- 3 sites in China
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- Guangzhou Chia Tai Innovative Pharmaceutical Co., Ltd.
Healthy
A Study in Men With Overweight to Test How Well Different Doses of BI 1820237 Are Tolerated When Given as an Injection Alone or in Combination With Liraglutide
The main objective of this trial is to investigate safety, tolerability and pharmacokinetics (PK) and pharmacodynamics (PD) of BI 1820237 alone or together with a single low dose of liraglutide in male subjects with…
- Trial name
- NCT04903509
- Testing
- BI 1820237, Saxenda®, Paracetamol-ratiopharm®
- Where
- Germany
- Volunteers
- 95 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Overweight or Obesity, Diabetes
A Study of SYH2069 Injection in Healthy Participants
To evaluate the safety and tolerability of single and multiple doses of SYH2069 Injection in healthy participants.
- Trial name
- NCT07736391
- Testing
- SYH2069 Injection
- Where
- China
- Volunteers
- 104 people, healthy volunteers welcome
- Sponsor
- CSPC Ouyi Pharmaceutical Co., Ltd.
Healthy Subjects, Obesity
Phase 1/1b Study of TLC-6740 in Healthy Subjects and Subjects With Obesity, With or Without Diabetes
The phase 1 portion of the study is designed to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of TLC-6740 after single- and multiple-ascending doses in healthy subjects.
- Conditions
- Healthy Subjects, Obesity, Type 2 Diabetes
- Trial name
- NCT05822544
- Testing
- TLC-6740 Oral Solution, TLC-6740 Tablet, Drug Metabolizing Enzyme
- Where
- 4 sites in New Zealand
- Volunteers
- 564 people, healthy volunteers welcome
- Sponsor
- OrsoBio, Inc
Overweight , Obesity
Phase 1 Clinical Study of MWN110 Injection in Healthy Participants and Overweight or Obese Participants
This study is a multicenter, randomized, double-blind, placebo-controlled, single and multiple ascending-dose phase 1 clinical trial aimed at evaluating the safety, tolerability, PK, PD, and immunogenicity of MWN110 Injection in…
- Trial name
- NCT07779980
- Testing
- MWN110
- Where
- China
- Volunteers
- 103 people, healthy volunteers welcome
- Sponsor
- Shanghai Minwei Biotechnology Co., Ltd
Healthy Volunteer
A Drug-Drug Interaction Study Between PF-06882961 and PF-06865571 in Healthy Adult Participants and Overweight Adults or Adults With Obesity Who Are Otherwise Healthy
This study will be conducted in 2 parts. Part A will investigate the potential effect of PF-06865571 on the pharmacokinetics (PK) of PF-06882961 in healthy adult participants.
- Trial name
- NCT04839393
- Testing
- PF-06882961 followed by PF-06882961/PF-06865571, PF-06882961/PF-06865571 followed by PF-06882961, PF-06882961 + PF-06865571
- Where
- United States
- Volunteers
- 27 people, healthy volunteers welcome
- Sponsor
- Pfizer
Overweight or Obesity
A Study of SYH2082 Injection in Healthy Participants
To evaluate the safety and tolerability of single dose of SYH2082 Injection in healthy participants.
- Trial name
- NCT07736404
- Testing
- SYH2082 Injection
- Where
- China
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- CSPC Ouyi Pharmaceutical Co., Ltd.
Diabetes Mellitus, Type 2
Study to Determine the Utility of Novel Technologies and Biomarkers to Measure Human Response to Rosiglitazone Maleate
Insulin resistance (IR) is common in many metabolic disorders and predisposes an individual to Type 2 Diabetes Mellitus (T2DM), the Metabolic Syndrome and coronary atherosclerosis.
- Trial name
- NCT00551564
- Testing
- rosiglitazone maleate
- Where
- United States
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Healthy Volunteers
High-intensity Interval Training on the Self-esteem, Basal Metabolic Rate and Muscle Mass in Overweight Women.
Overweight and obesity are a public health problem for society, reflected by an increase in its prevalence worldwide, being more frequent in women and related to low levels of self-esteem, accumulation of subcutaneous fat and…
- Trial name
- NCT03852043
- Testing
- High-intensity interval training, Moderate-intensity continuous training
- Where
- Colombia
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- Universidad de Antioquia
Obese or Overweight Healthy Volunteers, Type 2 Diabetes Mellitus (T2DM)
A Study to Evaluate ALN-4324 in Overweight to Obese Healthy Volunteers and in Overweight to Obese Patients With T2DM
The purpose of this study is to: evaluate the safety and tolerability of single ascending doses of ALN-4324 in healthy volunteers and to characterize the single-dose PK of ALN-4324 evaluate the efficacy, safety, tolerability, PK…
- Trial name
- NCT06845202
- Testing
- ALN-4324
- Where
- 22 sites in United States, Argentina and 4 more
- Volunteers
- 105 people, healthy volunteers welcome
- Sponsor
- Alnylam Pharmaceuticals
Healthy, Overweight
A Study of LY4086940 in Healthy Participants and Participants With Overweight or Obesity, With or Without Type 2 Diabetes
The main purpose of this study is to evaluate the safety, tolerability of LY4086940 and how it is processed in the body. Participation in Part A of the study will last about 10 weeks and may include up to 6 visits.
- Conditions
- Healthy, Overweight, Obesity, Type 2 Diabetes
- Trial name
- NCT06945419
- Testing
- LY4086940
- Where
- 5 sites in United States, Singapore
- Volunteers
- 219 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Healthy, Overweight and/or Obese Subjects
Clinical Trial to Study the Safety Tolerability, Pharmacokinetics, Food Effect & Pharmacodynamics of a New Compound P7435 in Healthy, Overweight and/or Obese Subjects
Clinical trial to study the safety tolerability, pharmacokinetics, food effect and pharmacodynamics of a new compound P7435 in in healthy, overweight and/or obese subjects
- Trial name
- NCT01764425
- Testing
- P7435
- Where
- 2 sites in India
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Piramal Enterprises Limited